PMID- 35535267
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220716
IS  - 1179-1322 (Print)
IS  - 1179-1322 (Electronic)
IS  - 1179-1322 (Linking)
VI  - 14
DP  - 2022
TI  - Decaprenyl Diphosphate Synthase Subunit 1 (PDSS1): A Potential Prognostic 
      Biomarker and Immunotherapy-Target for Hepatocellular Carcinoma.
PG  - 1627-1639
LID - 10.2147/CMAR.S364346 [doi]
AB  - PURPOSE: PDSS1 (decaprenyl diphosphate synthase subunit 1) plays an important 
      role in the progression of several types of tumor. However, the biological 
      functions of PDSS1 remain unclear in patients with hepatocellular carcinoma 
      (HCC). In this study, We attempted to determine the role of PDSS1 in predicting 
      the survival and efficacy of immunotherapy for HCC patients. METHODS: We analyzed 
      the expression of PDSS1 in pan-cancer by Tumor Immune Estimation Resource (TIMER) 
      and UALCAN database. Next, we investigated the correlations between the 
      expression and potential prognostic value of PDSS1 in pan-cancer by Gene 
      Expression Profiling Interactive Analysis (GEPIA) and Kaplan-Meier plotter and 
      further confirmed our finding in our study of 139 patients with HCC. Furthermore, 
      we correlated expression patterns with the presence of immune cell infiltrates 
      and immune regulatory molecules in HCC tissue by TIMER. Finally, its potential 
      immune-related mechanism was explored by Gene Set Enrichment Analysis (GSEA). 
      RESULTS: Multiple datasets demonstrate that PDSS1 is up-regulated in HCC tissues 
      compared with adjacent tissues, which was validated at mRNA (databases) and 
      protein levels (our cohort). Patients with higher PDSS1 expression had shorter 
      overall survival and relapse-free survival. In addition, PDSS1 expression was 
      positively related to early recurrence and served as an independent poor 
      prognostic factor for HCC. Patients with higher PDSS1 expression had lower CD8+ T 
      cells in HCC tissue, and PDSS1 deteriorates T cell exhaustion by promoting T cell 
      surface inhibitory receptors' secretion and immunosuppressive cell proliferation. 
      Furthermore, PDSS1 was positively correlated with the WNT, TGFbeta, VEGF, and other 
      signaling pathways in HCC. CONCLUSION: PDSS1 is a potential prognostic biomarker 
      and immunotherapy target for hepatocellular carcinoma.
CI  - (c) 2022 Yang et al.
FAU - Yang, Yuping
AU  - Yang Y
AD  - Department of Gastroenterology, The First Affiliated Hospital of Jinan 
      University, Jinan University, Guangzhou, Guangdong Province, 510630, People's 
      Republic of China.
FAU - Li, Jinying
AU  - Li J
AD  - Department of Gastroenterology, The First Affiliated Hospital of Jinan 
      University, Jinan University, Guangzhou, Guangdong Province, 510630, People's 
      Republic of China.
FAU - Tang, Ming
AU  - Tang M
AD  - Department of Gastroenterology, The First Affiliated Hospital of Jinan 
      University, Jinan University, Guangzhou, Guangdong Province, 510630, People's 
      Republic of China.
FAU - Nie, Biao
AU  - Nie B
AD  - Department of Gastroenterology, The First Affiliated Hospital of Jinan 
      University, Jinan University, Guangzhou, Guangdong Province, 510630, People's 
      Republic of China.
FAU - Huang, Wei
AU  - Huang W
AUID- ORCID: 0000-0002-3169-5031
AD  - Department of Gastroenterology, The First Affiliated Hospital of Jinan 
      University, Jinan University, Guangzhou, Guangdong Province, 510630, People's 
      Republic of China.
LA  - eng
PT  - Journal Article
DEP - 20220503
PL  - New Zealand
TA  - Cancer Manag Res
JT  - Cancer management and research
JID - 101512700
PMC - PMC9078875
OTO - NOTNLM
OT  - decaprenyl diphosphate synthase subunit 1
OT  - hepatocellular carcinoma
OT  - prognosis
OT  - tumor microenvironment
COIS- The authors declare that they do not have any competing interests in this work.
EDAT- 2022/05/11 06:00
MHDA- 2022/05/11 06:01
PMCR- 2022/05/03
CRDT- 2022/05/10 01:50
PHST- 2022/02/28 00:00 [received]
PHST- 2022/04/27 00:00 [accepted]
PHST- 2022/05/10 01:50 [entrez]
PHST- 2022/05/11 06:00 [pubmed]
PHST- 2022/05/11 06:01 [medline]
PHST- 2022/05/03 00:00 [pmc-release]
AID - 364346 [pii]
AID - 10.2147/CMAR.S364346 [doi]
PST - epublish
SO  - Cancer Manag Res. 2022 May 3;14:1627-1639. doi: 10.2147/CMAR.S364346. eCollection 
      2022.